search
Back to results

A Clinical Trial to Compare the Safety, Tolerability, and PK Properties of DA-5216 and DA-5216-R and to Evaluate the Food Effect on DA-5216.

Primary Purpose

Healthy

Status
Recruiting
Phase
Phase 1
Locations
Korea, Republic of
Study Type
Interventional
Intervention
DA-5216
DA-5216-R
DA-5216
DA-5216
Sponsored by
Dong-A ST Co., Ltd.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Healthy

Eligibility Criteria

19 Years - 50 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Healthy male and female volunteer 19 years to 50 years
  • Body weight in the range of 50.0kg and body mass index in the range of 18 to 27kg/m2
  • Subject who are negative in pregnancy test or pregnant or Lactating women
  • The subjects personally signed and dated informed consent document after informed of all patient aspects of the study, fully understanding and determined spontaneously to participate
  • The subjects who are judged appropriate to participate this clinical trial according to the physical examination, routine laboratory examination and questionnaire

Exclusion Criteria:

  • Subject with serious active hepatobiliary, respiratory, digestive, hematologic, endocrine(diabetes mellitus, aldosteronism), immunologic, cardiovascular(hypertension, angina, heart failure, myocardial infarction, etc.), neurologic, urologic, otorhinolaryngologic, musculoskeletal, psychological disease or history of such disease
  • Subject with gastrointestinal disease (Crohn's disease, peptic ulcer, acute or chronic pancreatitis, etc.) or history of such disease/surgery (excluding simple appendic surgery, hernia surgery, hemorrhoid surgery).
  • Subject who have galactose intolerance, Lapp lactase deficiency or glucose galactose malabsorption
  • Subject who have had one or more of the following findings

    • AST, ALT > 1.5 times the upper limit
    • CPK > 2.5 times the upper limit
    • eGFR <60mL/min/1.73m2

Sites / Locations

  • Seoul National University HospitalRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Experimental

Experimental

Experimental

Experimental

Arm Label

[Part A] DA-5216

[Part A] DA-5216-R

[Part B] DA-5216(Fasting)

[Part B] DA-5216(Fed)

Arm Description

Outcomes

Primary Outcome Measures

Peak Plasma Concentration (Cmax) PK parameter
Area under the plasma concentration versus time curve (AUClast) PK parameter

Secondary Outcome Measures

Full Information

First Posted
August 16, 2022
Last Updated
September 21, 2022
Sponsor
Dong-A ST Co., Ltd.
search

1. Study Identification

Unique Protocol Identification Number
NCT05506007
Brief Title
A Clinical Trial to Compare the Safety, Tolerability, and PK Properties of DA-5216 and DA-5216-R and to Evaluate the Food Effect on DA-5216.
Official Title
A Randomized, Open-label, Single Dose, Cross-over Clinical Trial to Compare the Safety, Tolerability, and Pharmacokinetic Properties of DA-5216 and DA-5216-R and to Evaluate the Food Effect on DA-5216 in Healthy Adult Subjects.
Study Type
Interventional

2. Study Status

Record Verification Date
August 2022
Overall Recruitment Status
Recruiting
Study Start Date
August 29, 2022 (Actual)
Primary Completion Date
October 2022 (Anticipated)
Study Completion Date
October 2022 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Dong-A ST Co., Ltd.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
This is a randomized, open-label, single dose, 2-part, cross-over clinical trial to compare the safety, tolerability, and pharmacokinetic properties of DA-5216 and DA-5216-R and to evaluate the food effect on DA-5216 in healthy adult subjects

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Healthy

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Crossover Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
88 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
[Part A] DA-5216
Arm Type
Experimental
Arm Title
[Part A] DA-5216-R
Arm Type
Experimental
Arm Title
[Part B] DA-5216(Fasting)
Arm Type
Experimental
Arm Title
[Part B] DA-5216(Fed)
Arm Type
Experimental
Intervention Type
Drug
Intervention Name(s)
DA-5216
Intervention Description
During the cross-over [Part A], patients will be randomly assigned to receive one of the following treatment sequences: Sequence I. Single dose of DA-5216-R(Fasting) on Day 1 followed by a single dose of DA-5216(Fasting) on Day 8. Sequence II. Single dose of DA-5216(Fasting) on Day 1 followed by a single dose of DA-5216-R(Fasting) on Day 8.
Intervention Type
Drug
Intervention Name(s)
DA-5216-R
Intervention Description
During the cross-over [Part A], patients will be randomly assigned to receive one of the following treatment sequences: Sequence I. Single dose of DA-5216-R(Fasting) on Day 1 followed by a single dose of DA-5216(Fasting) on Day 8. Sequence II. Single dose of DA-5216(Fasting) on Day 1 followed by a single dose of DA-5216-R(Fasting) on Day 8.
Intervention Type
Drug
Intervention Name(s)
DA-5216
Intervention Description
During the cross-over [Part B], patients will be randomly assigned to receive one of the following treatment sequences: Sequence I. Single dose of DA-5216(Fasting) on Day 1 followed by a single dose of DA-5216(Fed) on Day 8. Sequence II. Single dose of DA-5216(Fed) on Day 1 followed by a single dose of DA-5216(Fasting) on Day 8.
Intervention Type
Drug
Intervention Name(s)
DA-5216
Intervention Description
During the cross-over [Part B], patients will be randomly assigned to receive one of the following treatment sequences: Sequence I. Single dose of DA-5216(Fasting) on Day 1 followed by a single dose of DA-5216(Fed) on Day 8. Sequence II. Single dose of DA-5216(Fed) on Day 1 followed by a single dose of DA-5216(Fasting) on Day 8.
Primary Outcome Measure Information:
Title
Peak Plasma Concentration (Cmax) PK parameter
Time Frame
0~48hours
Title
Area under the plasma concentration versus time curve (AUClast) PK parameter
Time Frame
0~48hours

10. Eligibility

Sex
All
Minimum Age & Unit of Time
19 Years
Maximum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Healthy male and female volunteer 19 years to 50 years Body weight in the range of 50.0kg and body mass index in the range of 18 to 27kg/m2 Subject who are negative in pregnancy test or pregnant or Lactating women The subjects personally signed and dated informed consent document after informed of all patient aspects of the study, fully understanding and determined spontaneously to participate The subjects who are judged appropriate to participate this clinical trial according to the physical examination, routine laboratory examination and questionnaire Exclusion Criteria: Subject with serious active hepatobiliary, respiratory, digestive, hematologic, endocrine(diabetes mellitus, aldosteronism), immunologic, cardiovascular(hypertension, angina, heart failure, myocardial infarction, etc.), neurologic, urologic, otorhinolaryngologic, musculoskeletal, psychological disease or history of such disease Subject with gastrointestinal disease (Crohn's disease, peptic ulcer, acute or chronic pancreatitis, etc.) or history of such disease/surgery (excluding simple appendic surgery, hernia surgery, hemorrhoid surgery). Subject who have galactose intolerance, Lapp lactase deficiency or glucose galactose malabsorption Subject who have had one or more of the following findings AST, ALT > 1.5 times the upper limit CPK > 2.5 times the upper limit eGFR <60mL/min/1.73m2
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Seung Hwan Lee, PhD
Phone
02-2072-2343
Email
leejh413@snu.ac.kr
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Seung Hwan Lee, PhD
Organizational Affiliation
SNUH Clinical Pharmacololgy and Therapeutics
Official's Role
Principal Investigator
Facility Information:
Facility Name
Seoul National University Hospital
City
Soeul
Country
Korea, Republic of
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Seung Hwan Lee, PhD

12. IPD Sharing Statement

Learn more about this trial

A Clinical Trial to Compare the Safety, Tolerability, and PK Properties of DA-5216 and DA-5216-R and to Evaluate the Food Effect on DA-5216.

We'll reach out to this number within 24 hrs